|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient.
|
30151614 |
2018 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
This CLN-Ohi-MB biochip could quantify single-point mutations in KRAS mRNA (G12C, G12D, G12V) in pancreatic cancer cell-derived EVs and single-point mutations in EGFR mRNA (L858R and T790M) in lung cancer cell-derived EVs with high specificity, not achievable by conventional molecular probes.
|
30145409 |
2018 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Several ultra-sensitive methods for T790M in plasma cell-free DNA (cfDNA) have been developed for lung cancer.
|
30444875 |
2018 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review.
|
29907952 |
2018 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Pitfalls in diagnosis with the use of circulating tumor-derived epidermal growth factor receptor mutations in lung cancer harboring pretreatment T790M.
|
29063709 |
2018 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Changes of T790M in serum/plasma in <i>EGFR</i>-mutant lung cancer patients with T790M-AR might be a useful marker of symptomatic and radiographic outcome to osimertinib.
|
29930751 |
2018 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Therefore, germline <i>EGFR</i> T790M mutations result in a unique inherited lung cancer syndrome targeting never smokers.
|
30225213 |
2018 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our drug inhibition studies indicate that these activating insertion mutations respond more favorably to osimertinib, a recently Food and Drug Administration-approved EGFR inhibitor for T790M-positive patients with lung cancer.
|
30104348 |
2018 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
|
30276451 |
2018 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Different resistance mechanisms, especially, T790M secondary acquired point mutation and in some cases amplification of cMET, have been a major setback for the lung cancer therapies.
|
28362115 |
2017 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>In silico</i> insight into EGFR treatment in patients with lung carcinoma and T790M mutations.
|
28565760 |
2017 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Amplification-refractory mutation system PCR has been used for the analysis of ctDNA to detect resistance-causing mutations in the epidermal growth factor receptor gene (eg, EGFR T790M) in lung cancer patients.
|
28732213 |
2017 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, we introduced the EGFR T790M mutation into the PC9 human lung cancer cell line-which has a deletion in exon 19 of the EGFR gene-by clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas)9-mediated genome editing.
|
28422737 |
2017 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Staurosporine scaffold-based rational discovery of the wild-type sparing reversible inhibitors of EGFR T790M gatekeeper mutant in lung cancer with analog-sensitive kinase technology.
|
27891677 |
2017 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
As this clinical entity is underrepresented in clinical trials, the practicability of plasma EGFR testing and the optimal dose-response relationship of osimertinib in T790M-positive lung cancer complicated with LM deserves further exploration.
|
28296233 |
2017 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Nowadays, 3rd generation EGFR TKI is widely used for T790M positive 1st and 2nd EGFR-TKI resistant lung cancer patients.
|
28684311 |
2017 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
|
27959700 |
2017 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer.
|
28082405 |
2017 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, we analyzed 55 cfDNA preparations from patients with lung cancer to compare reliability and sensitivity of the three methods under routine conditions and achieved 96.0% concordance of p.T790M results.
|
28723342 |
2017 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403.
|
27506489 |
2017 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The present study established lung cancer cell lines that were resistant to gefitinib or erlotinib, and these cell lines were verified to contain the <i>EGFR</i> T790M mutation.
|
28781659 |
2017 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Lung cancer harboring epidermal growth factor receptor (EGFR) mutations and treated with EGFR tyrosine kinase inhibitors (TKIs) all eventually develop acquired resistance to the treatment, with half of the patients developing EGFR T790M resistance mutations.
|
28620690 |
2017 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer.
|
28778263 |
2017 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Specifically, these agents can overcome the effects of the T790M mutation, which mediates resistance to first- and second-generation EGFR TKI, and recent clinical trials have documented their efficacy in patients with <i>EGFR</i>-mutant lung cancer.
|
28416483 |
2017 |
|
Carcinoma of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
|
27270313 |
2016 |